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grelor, standard & high dose Clopidogrel in patients undergoing PCI.
PubMed, EMBASE, CENTRAL and clinicaltrials.gov were searched for
studies comparing Prasugrel, Ticagrelor, standard dose (SD) & high
dose (HD) Clopidogrel in patients undergoing PCI. Frequentist and
Bayesian random effect network meta-analyses were performed be-
sides random effect direct pairwise comparisons. Statistical analysis
was conducted using WinBugs and Stata software. Ranking of treat-
ments are based on surface under cumulative ranking curves (SUCRA)
derived from Bayesian analysis. SUCRA values provide chances of
being best drug in form of percentage (%).
RESULTS Thirty trials, with 34, 563 person years of follow up data
after PCI, were included in the analysis. Prasugrel (86%) emerged
as best drug to prevent deﬁnite or probable stent thrombosis,
followed by Clopidogrel HD (66%) and Ticagrelor (44%), with Clo-
pidogrel SD being the worst. Myocardial infarction was least likely
to be prevented by Clopidogrel SD (0%) after PCI, and rest three
were superior to it (Prasugrel 74%; Clopidogrel 70%; Ticagrelor
56%). Clopidogrel SD (18%) was least effective in preventing car-
diovascular deaths after PCI. Prasugrel (73%) was likely most
effective in preventing cardiovascular deaths followed by Ticagrelor
(62%) and Clopidogrel HD (47%). Ticagrelor (68%) reduced all-cause
mortality by a small margin compared to rest of treatments (Pra-
sugrel 50%; Clopidogrel 48%; Clopidogrel 34%). Clopidogrel SD
(79%), followed by Clopidogrel HD (53%) and Ticagrelor (48%),
resulted in signiﬁcantly lower TIMI major bleeding complications
compared to Prasugrel. Analysis of any bleeding revealed similar
trend. Clopidogrel HD performed better than Prasugrel in terms of
bleeding complications. Results of direct pairwise comparison and
network meta-analysis were consistent in the direct of overall ef-
fect (Figure).
CONCLUSIONS Prasugrel is most effective drug to prevent post PCI
ischemic events but at the expense of higher bleeding. Ticagrelor
followed by Clopidogrel HD appears to strike the right balance be-
tween efﬁcacy & safety.
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BACKGROUND Primary angioplasty is the best reperfusion treatment
in ST elevated myocardial infarction. The number of elderly patients
(> 75 years) undergoing primary angioplasty is progressively
increasing as population is ageing. The optimal antithrombotic ther-
apy during the procedure (bivalirudin vs. unfractioned heparin with
or without abciximab) is not deﬁned for this important subgroup of
patients.
METHODS Retrospective consecutive registry conducted in 31 centers
of patients > 75 years with ST elevation myocardial infarction un-
dergoing primary angioplasty.
RESULTS A total of 3,126 pts have been included, 2,029 (64.9%)
treated only with UFH, 750 (24%) with UFH+abciximab, 319 (10.2%)
with bivalirudin only and 28 (0.9%) with bivalirudin+abciximab.
Three groups were deﬁned: BIV (319), UFH (2.029) and UFH-A (750)
with mean ages 81.25, 81.6 4.7 and 79.6 4.3 years respectively
(p<0.001).. Outcomes at 12 months were the following: survival free of
cardiac death and MI was 85.6%, 80% and 83.4% (p¼0.01) in BIV, UFH
and UFH-A groups and TLR was 2.7%, 3% and 1.4% (p¼0.1) respec-
tively. Incidences of deﬁnite or probable stent thrombosis were 2.8%,
2.5% and 2.3% (p¼0.2) and incidences of bleeding BARC > 2 were
0.8%, 1.3% and 1.5% (p¼0.1) respectively.
CONCLUSIONS The most common antithrombotic treatment in pri-
mary angioplasty of the very elderly is based on UFH (89%) with the
use of abciximab in a 24% of cases. The use of bivalirudin was asso-
ciated with the lowest incidence of cardiac death and MI with no in-
crease in stent thrombosis. The rate of severe bleeding (BARC >2) was
comparable.
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BACKGROUND Some patients have high residual platelet reactivity
on clopidogrel after coronary intervention and risk of thbombotic
events is high. The aim of the study was to investigate safety and
efﬁcacy of policosanol in patients with high on-treatment platelet
reactivity after drug-eluting stent implantation.
